All Stories

  1. Language-based Assessments for Experienced Well-being: Accuracy and External Validity Across Behaviors, Traits, and States
  2. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder
  3. Tapping into alcohol use during COVID: Drinking correlates among bartenders and servers
  4. Language-based EMA assessments help understand problematic alcohol consumption
  5. An integrated LSTM-HeteroRGNN model for interpretable opioid overdose risk prediction
  6. Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth
  7. Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State
  8. Compassion within conflict: Toward a computational theory of social groups informed by maternal brain physiology
  9. Where Opioid Overdose Patients Live Far From Treatment: Geospatial Analysis of Underserved Populations in New York State (Preprint)
  10. Comparison of Methods for Alcohol and Drug Screening in Primary Care Clinics
  11. Identifying risk of opioid use disorder for patients taking opioid medications with deep learning
  12. Association of Opioid Use Disorder With 2016 Presidential Voting Patterns: Cross-sectional Study in New York State at Census Tract Level
  13. Predicting opioid overdose risk of patients with opioid prescriptions using electronic health records based on temporal deep learning
  14. A large-scale retrospective study of opioid poisoning in New York State with implications for targeted interventions
  15. Detection of Suicidality Among Opioid Users on Reddit: Machine Learning–Based Approach
  16. Association of Opioid Use Disorder With 2016 Presidential Voting Patterns: A Cross-Sectional Study in New York State at Census Tract Level
  17. Trends and Patterns of Opioid Epidemic: A Large-Scale Retrospective Study of Hospital Visits with Opioid Poisoning in New York State, 2010-2016
  18. Advocacy and Public Policy Efforts of the American Academy of Addiction Psychiatry
  19. Commentary: Proposed Model State Cannabis Laws to Reduce Harms
  20. Association of Opioid Use Disorder With 2016 Presidential Voting Patterns: Cross-sectional Study in New York State at Census Tract Level (Preprint)
  21. Recommended Use of Terminology in Addiction Medicine
  22. Predicting Opioid Overdose Risk of Patients with Opioid Prescriptions Using Electronic Health Records Based on Temporal Deep Learning
  23. Detection of Suicidality Among Opioid Users on Reddit: Machine Learning–Based Approach (Preprint)
  24. Novel Formulations of Buprenorphine for Treatment of Opioid Use Disorder
  25. Gabapentin Enacarbil Extended‐Release for Alcohol Use Disorder: A Randomized, Double‐Blind, Placebo‐Controlled, Multisite Trial Assessing Efficacy and Safety
  26. Dispositional Neural Signatures: When Group Main Effects on Functional Magnetic Resonance Imaging Tasks Can Still Be Interesting
  27. Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staff
  28. Medications for addiction treatment (MAT)
  29. Advances in the delivery of buprenorphine for opioid dependence
  30. Long-Term Buprenorphine Implants for Treatment of Opioid Dependence: Safety Outcomes from Two Open-Label Extension Trials
  31. Blood Levels of Monoamine Precursors and Smoking in Patients with Schizophrenia
  32. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine
  33. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone
  34. Implications of Epidemiological Data for Identifying Persons with Substance Use and Other Mental Disorders
  35. Correlates to the variable effects of cannabis in young adults: a preliminary study
  36. Buprenorphine Implants for Treatment of Opioid Dependence
  37. Does a History of Alcohol Use Disorder Affect Response to Antidepressant Medication in Patients With Dysthymic Disorder?
  38. Techniques of Individual Supportive Psychotherapy
  39. Acamprosate: Safety and Tolerability in the Treatment of Alcohol Dependence
  40. Cerebral metabolism and mood in remitted opiate dependence
  41. Reply to Dr Caputo and Colleagues Regarding "GABAergic Medications for Treating Alcohol Dependence"
  42. Advances in the Treatment of Alcohol Dependence
  43. Genomewide suggestive linkage of opioid dependence to chromosome 14q
  44. Current and Future Drug Therapies for Alcohol Dependence
  45. New Developments in Addiction Treatment
  46. A Randomized, Open‐Label, Controlled Trial of Gabapentin and Phenobarbital in the Treatment of Alcohol Withdrawal
  47. Improving the Care of Individuals with Schizophrenia and Substance Use Disorders: Consensus Recommendations
  48. Sports Chronobiology Consultation: From the Lab to the Arena
  49. Development of Service Intensity Criteria and Program Categories for Individuals with Co-Occurring Disorders
  50. Dual Diagnosis
  51. Dual Diagnosis: Alcoholism and Co‐Morbid Psychiatric Disorders
  52. Integrating Services for Schizophrenia and Substance Abuse
  53. Pilot Study of Bright-Light Therapy Reflected Toward the Eyes for the Pruritus of Chronic Liver Disease
  54. Psychiatric Symptom Severity and Length of Stay on an Intensive Rehabilitation Unit
  55. Treatment of Dementia-Associated Agitation With Gabapentin
  56. Depression and Demoralization Among Russian-Jewish Immigrants in Primary Care
  57. Early Augmentation of Sertraline With Methylphenidate
  58. A Pilot Open Randomized Trial of Valproate and Phenobarbital in the Treatment of Acute Alcohol Withdrawal
  59. Transient Psychosis With Psychogenic Polydipsia in Schizotypal Patient Taking Fluoxetine
  60. Is schizophrenia addiction prone?
  61. Negative Symptoms in Stroke Patients and Length of Hospital Stay
  62. Prediction of Compliance With Outpatient Referral in Patients With Schizophrenia and Psychoactive Substance Use Disorders
  63. Methylphenidate treatment of negative symptoms in patients with dementia
  64. Differential Diagnosis of Substance-induced Psychosis and Schizophrenia in Patients With Substance Use Disorders
  65. A Preliminary Study of Therapeutic Alliance and Dually Diagnosed Inpatients
  66. Physical examination of substance abusers
  67. A Prospective Study of Integrated Outpatient Treatment for Substance‐Abusing Schizophrenic Patients
  68. Positive and negative syndrome typology in schizophrenic patients with psychoactive substance use disorders
  69. The feasibility of smoking bans on psychiatric units
  70. A Model of Integrated Services for Outpatient Treatment of Patients With Comorbid Schizophrenia and Addictive Disorders
  71. Integrated services for treatment of schizophrenic substance abusers: Demographics, symptoms, and substance abuse patterns
  72. DEVELOPMENT OF NICOTINIC RESPONSES IN THE RAT ADRENAL MEDULLA AND LONG‐TERM EFFECTS OF NEONATAL NICOTINE ADMINISTRATION